New CAR t therapy targets tough leukemia in early trial

NCT ID NCT06326021

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment called FL-33 CAR T for people with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack leukemia cells. The study aims to find the safest and most effective dose, enrolling up to 27 participants aged 1 to 70.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BeijingGoBroadH

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Liquan Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 201418, China

  • The General Hospital of Western Theater Command PLA

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610083, China

  • Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200435, China